With $3bn Viela Acquisition, Horizon Builds A Pipeline
Horizon will gain the commercial product Uplizna and three pipeline products for rare diseases, where it can build on its success with Tepezza. Horizon is also interested in Viela's R&D team.
You may also be interested in...
The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sj
The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.